Ruxolitinib inhibits IFNγ licensing of human bone marrow derived Mesenchymal Stromal Cells

BACKGROUND: Ruxolitinib is a JAK2/JAK1 inhibitor which blocks inflammatory JAK-STAT signaling pathway. Ruxolitinib has been demonstrated to be effective in the treatment of steroid-resistant acute Graft vs Host Disease (GvHD). Ruxolitinib’s effect on inflammatory cells of hematopoietic origin is kno...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Transplant Cell Ther
Autori principali: Ryan, Molly Mercedes, Patel, Mihir, Hogan, Keenan, Lipat, Ariel Joy, Scandolara, Rafaela, Das, Rahul, Bruker, Charles, Galipeau, Jacques, Chinnadurai, Raghavan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8110949/
https://ncbi.nlm.nih.gov/pubmed/33965175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtct.2021.02.002
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi